In the GEOMETRY mono-1 trial, a multicentre, open-label phase II study evaluated the efficacy and safety of capmatinib monotherapy in adult patients with EGFR wildtype, ALK-negative rearrangement, advanced NSCLC harbouring METex14 skipping mutations and/or MET amplification [35]. The gene discussed is MET; the disease is non-small cell lung carcinoma.